1. Home
  2. MOMO vs GYRE Comparison

MOMO vs GYRE Comparison

Compare MOMO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MOMO
  • GYRE
  • Stock Information
  • Founded
  • MOMO 2011
  • GYRE 2002
  • Country
  • MOMO China
  • GYRE United States
  • Employees
  • MOMO N/A
  • GYRE N/A
  • Industry
  • MOMO Computer Software: Prepackaged Software
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • MOMO Technology
  • GYRE Health Care
  • Exchange
  • MOMO Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • MOMO 909.4M
  • GYRE 897.1M
  • IPO Year
  • MOMO 2014
  • GYRE N/A
  • Fundamental
  • Price
  • MOMO $8.90
  • GYRE $7.49
  • Analyst Decision
  • MOMO Buy
  • GYRE
  • Analyst Count
  • MOMO 2
  • GYRE 0
  • Target Price
  • MOMO $10.00
  • GYRE N/A
  • AVG Volume (30 Days)
  • MOMO 1.4M
  • GYRE 189.9K
  • Earning Date
  • MOMO 09-02-2025
  • GYRE 08-12-2025
  • Dividend Yield
  • MOMO 3.53%
  • GYRE N/A
  • EPS Growth
  • MOMO N/A
  • GYRE N/A
  • EPS
  • MOMO 1.06
  • GYRE 0.02
  • Revenue
  • MOMO $1,450,201,337.00
  • GYRE $100,643,000.00
  • Revenue This Year
  • MOMO $0.97
  • GYRE $21.04
  • Revenue Next Year
  • MOMO $4.25
  • GYRE $89.64
  • P/E Ratio
  • MOMO $8.44
  • GYRE $93.64
  • Revenue Growth
  • MOMO N/A
  • GYRE N/A
  • 52 Week Low
  • MOMO $5.12
  • GYRE $6.11
  • 52 Week High
  • MOMO $8.95
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • MOMO 68.10
  • GYRE 42.81
  • Support Level
  • MOMO $8.48
  • GYRE $7.49
  • Resistance Level
  • MOMO $8.94
  • GYRE $7.80
  • Average True Range (ATR)
  • MOMO 0.24
  • GYRE 0.48
  • MACD
  • MOMO -0.06
  • GYRE 0.07
  • Stochastic Oscillator
  • MOMO 86.23
  • GYRE 40.48

About MOMO Hello Group Inc.

Hello Group Inc provides mobile-based social networking services. It enables users to establish and expand social relationships based on location and interests. Its platform includes the Momo mobile application and a variety of related features, functionalities, tools, and services that it provides to users, customers, and platform partners. The company derives its revenue from live video services, value-added services, mobile marketing services, mobile games, and other services. It operates in three segments: Momo's service lines, Tantan's service lines, and QOOL's service lines, out of which Momo's service lines segment derives the majority of revenue.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: